作者：
Ohkura,T. [1]
;
Ohta,K. [2]
;
Nagao,T. [3]
;
Kusumoto,K. [4]
;
Koeda,A. [5]
;
Ueda,T. [6]
;
Jomura,T. [7]
;
Ikeya,T. [8]
;
Ozeki,E. [9]
;
Wada,K. [10]
;
Naitoh,K. [11]
;
Inoue,Y. [12]
;
Takahashi,N. ;
Iwai,H. ;
Arakawa,H. ;
Ogihara,T.
作者单位：
Spheroid Working Group in Safety Evaluation Forum, Japan, Charles River Laboratories Japan Inc.,
[1]
Spheroid Working Group in Safety Evaluation Forum, Japan, Bioscience Research Center
[2]
Spheroid Working Group in Safety Evaluation Forum, Japan, Dainippon Sumitomo Pharma Co., Ltd.Osaka
[3]
Spheroid Working Group in Safety Evaluation Forum, Japan, Toyo Gosei Co., Ltd.Ichikawa, Japan
[4]
Spheroid Working Group in Safety Evaluation Forum, Japan, Pre-Clinical Research Department, Chugai
[5]
Spheroid Working Group in Safety Evaluation Forum, Japan, Ina Research Inc., Ltd.Ina, Japan
[6]
Spheroid Working Group in Safety Evaluation Forum, Japan, Sanwa Kagaku Kenkyusho Co., Ltd.Nagoya
[7]
Spheroid Working Group in Safety Evaluation Forum, Japan, Sanwa Kagaku Kenkyusho Co., Ltd.Inabe
[8]
Spheroid Working Group in Safety Evaluation Forum, Japan, Faculty of Pharmacy, Takasaki University
[9]
Spheroid Working Group in Safety Evaluation Forum, Japan, Janssen Pharmaceutical K.KTokyo, Japan
[10]
Faculty of Pharmacy, Takasaki University of Health and WelfareTakasaki, Japan
[11]
Spheroid Working Group in Safety Evaluation Forum, Japan, Maruishi Pharmaceutical Co., Ltd., 2-4-2
[12]
发布时间
2017-04-06
换一批
换一批
